Stifel Maintains Buy on Enliven Therapeutics, Raises Price Target to $82
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Stifel analyst Dara Azar maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $80 to $82.
Stifel analyst Dara Azar maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $80 to $82.